Randomized Trialhigh evidence
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.
JAMA neurology·October 5, 2026·PMID 42832215
Why it mattersEarly, continuous high-efficacy therapy in relapsing MS yields durable protection against disability milestones, including progression independent of relapse activity. These long-term data help neurologists counsel patients on the benefits of initiating ocrelizumab promptly rather than escalating later.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled